WATERS Business Summary

Waters Corporation (WAT) is a global leader in analytical instrumentation, generating revenue through the sale of high-performance liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis systems, alongside a high-margin recurring stream from precision chemistry consumables and technical services. As of February 2026, the company has completed a transformative $18.8 billion acquisition of BD Biosciences and Diagnostic Solutions, restructuring its operations into four primary segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. This pivot significantly expands its footprint in clinical diagnostics and cellular analysis, complementing its core strength in pharmaceutical quality control and research. Waters maintains a dominant 40% global share in the HPLC market and holds the number two position in mass spectrometry, competing directly with Agilent Technologies, Thermo Fisher Scientific, and Danaher Corporation (SCIEX). Founded in 1958 by James Logan Waters, the company is currently led by President and CEO Dr. Udit Batra, a chemical engineer and former CEO of MilliporeSigma who has modernized the firm’s commercial execution and accelerated its transition to a subscription-based software model via the Empower platform. The executive team includes SVP and CFO Amol Chaubal, SVP of Global Research & Strategy Dr. Daniel Rush, and division heads Rob Carpio (Analytical Sciences), Steve Conly (Biosciences), and Jianqing Bennett (Advanced Diagnostics). The board is chaired by Flemming Ørnskov, M.D., and recently added world-renowned genome scientist Dr. Claire M. Fraser following the BD transaction. Waters is characterized by high institutional ownership, with approximately 94% of shares held by major investment firms, reflecting its status as a cornerstone of the life sciences tools sector.